SST抗体

+ +

•  

   

     Western blot analysis of Mitofusin 1 in 3T3, mouse brain lysates using Mitofusin 1 antibody.    

  
  

•  

   

     Western blot analysis of Mitofusin 1 in CHO-K1, C6 lysates using Mitofusin 1 antibody.    

  
  

Somatostatin (SST) antibodies are essential tools in biomedical research and diagnostics, targeting the neuropeptide somatostatin. SST, discovered in 1973. is a regulatory hormone produced in the central nervous system, pancreas, and gastrointestinal tract. It exists in two bioactive forms (SST-14 and SST-28) and exerts inhibitory effects on hormone secretion (e.g., growth hormone, insulin, glucagon) via interaction with five G protein-coupled receptors (SSTR1-5). Its roles span physiological processes like neurotransmission, cell proliferation, and endocrine regulation.

SST antibodies are widely used to localize and quantify SST-expressing cells in tissues, particularly in studying neuroendocrine systems and diseases. For example, they help identify SST-producing tumors (e.g., pituitary adenomas, pancreatic neuroendocrine tumors) and assess SST receptor expression in cancers, guiding targeted therapies such as somatostatin analogs or peptide receptor radionuclide therapy (PRRT). These antibodies also support diabetes and gastrointestinal disorder research by mapping SST’s role in modulating insulin and gut motility.

Available as monoclonal or polyclonal variants, SST antibodies are validated for techniques like immunohistochemistry, ELISA, and Western blot. Recent advancements focus on improving antibody specificity and developing conjugates for imaging or therapeutic applications. Their versatility makes them indispensable in both mechanistic studies and clinical diagnostics, bridging insights into SST’s pathophysiology and therapeutic potential.